Please login to the form below

Not currently logged in
Email:
Password:

tisagenleucel

This page shows the latest tisagenleucel news and features for those working in and with pharma, biotech and healthcare.

Axovant bets on gene therapy with $842.5m Oxford BioMedica deal

Axovant bets on gene therapy with $842.5m Oxford BioMedica deal

tisagenleucel). Axovant CEO Pavan Cheruvu, who took the helm of the company after David Hung and other senior execs resigned in the wake of the intepirdine failure, said the company will

Latest news

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
certain health

Transforming the way health brands and companies communicate, we deliver creative science led, insight-driven solutions that give award winning results...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...